Editas Medicine, Inc.
Editas Medicine, Inc. (Nasdaq: EDIT) develops CRISPR-based gene-editing medicines for serious diseases, using Cas9 and Cas12a enzymes and engineered variants to modify DNA. Its research and development focuses on in vivo therapies, which edit cells inside the body, and on targeted lipid nanoparticle delivery. The lead… From the company’s description.
Over the twelve months to Jun 30, 2026, Editas Medicine, Inc. reported revenue of $47.01M, up 20.8% from a year earlier, and a net loss of $73.95M. Its operating margin was −161.4%, and operations used $119.86M in cash. In fiscal 2025, it reported revenue of $40.52M, up 25.4% from fiscal 2024, and a net loss of $160.06M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Editas Medicine, Inc. does
In the company’s own words
Editas Medicine, Inc. (Nasdaq: EDIT) develops CRISPR-based gene-editing medicines for serious diseases, using Cas9 and Cas12a enzymes and engineered variants to modify DNA. Its research and development focuses on in vivo therapies, which edit cells inside the body, and on targeted lipid nanoparticle delivery. The lead candidate, EDIT-401, is designed to increase LDL receptor expression and lower LDL cholesterol in people with hyperlipidemia, including heterozygous familial hypercholesterolemia. Other research includes in vivo editing of hematopoietic stem cells for sickle cell disease and transfusion-dependent beta thalassemia, as well as programs involving other cell types and tissues. Editas also collaborates with Bristol Myers Squibb on engineered T-cell medicines for cancer and autoimmune diseases and licenses gene-editing technology to partners, including Vertex and Immatics. The company discontinued plans to commercialize its former ex vivo candidate reni-cel in 2024 to focus resources on in vivo programs. Its website is www.editasmedicine.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1650664
- SIC
- 2836
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Editas Medicine, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Editas Medicine, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Editas Medicine, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Editas Medicine, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Editas Medicine, Inc.'s last four quarterly filings that the numbers alone won't show?”